KRYS - 2 Growth Stocks That Could Double in the Next Year
When fear rules the markets, investors usually have a hard time seeing the long-term benefits of stock investing. Even share prices of companies with potentially solid long-term prospects remain depressed. In such an environment it does become difficult to identify the real winners.
The good news is the market eventually recognizes a real long-term winner, re-adjusts its expectations about that company, and bids up its stock price. Two such potential long-term winners are biotechnology companies Krystal Biotech (NASDAQ: KRYS) and BioXcel Therapeutics (NASDAQ: BTAI) , and the market could well bid up their stocks over the next 12 months.
Biotechs that focus on gene-editing technologies have made a lot of noise in the past few years. Gene-editing refers to a collection of techniques that allow scientists to modify an organism's DNA. The technology promises to unlock therapies for difficult-to-treat illnesses. Krystal Biotech seeks to develop medicines using gene-editing primarily for dermatologic diseases.
For further details see:
2 Growth Stocks That Could Double in the Next Year